Efficacy and Safety of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL

This study is testing whether adding a second drug (xenobiotic agent) to a standard polatuzumab-based immunotherapy regimen improves outcomes for patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) — a fast-growing type of blood cancer — whose initial treatment response is insufficient after the first cycle. **You may be eligible if...** - You are between 18 and 75 years old - You have newly diagnosed, untreated CD20-positive DLBCL - Your cancer burden (IPI score) is moderate to high (2–5) - After your first cycle of treatment, a blood test (ctDNA) shows your cancer has not dropped enough - Your heart function is adequate (ejection fraction at least 50%) - Your general health is good (ECOG 0–2) **You may NOT be eligible if...** - You have already received treatment for DLBCL - You have serious organ dysfunction - You are pregnant or breastfeeding - You have uncontrolled infection Talk to your doctor to see if this trial is right for you.